Onpode
Cover art for An FDA-approved pancreatic cancer drug is now showing promise in early-stage lung cancer trials—expanding its therapeutic reach

An FDA-approved pancreatic cancer drug is now showing promise in early-stage lung cancer trials—expanding its therapeutic reach

November 13, 2026 · 8 min

David Sterling & Megan Skiendel

David, hey — you catch any of that oncology news out of August? Which part? There was a lot moving that month. August 26th specifically. I was sitting with a friend who's a GI oncologist — we were just having coffee — and her phone started going. And she looked up and said, 'They actually…

Rasonque (daraxonrasib), developed by Revolution Medicines, received FDA approval on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent treatment.

0:008:08
Get the next episode on Health →

Follow it free — new episodes land in your feed.

Or make your own — any topic, in minutes

More Onpode episodes on Health →

About this episode

Rasonque (daraxonrasib), developed by Revolution Medicines, received FDA approval on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent treatment.

Grounded in 6 sources
Therapeutic inhibition of RAS in non-small cell lung cancer ↗ · doi.org
EMA recommends authorisation of Rasonque for metastatic pancreatic cancer | European Medicines Agency (EMA) ↗ · ema.europa.eu
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer ↗ · fda.gov
Erasca Reports Third Quarter 2026 Business Updates and ↗ · globenewswire.com
Revolution Medicines Reports Third Quarter 2026 Financial ↗ · globenewswire.com
Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives ↗ · globenewswire.com
Read transcript

Megan Skiendel: David, hey — you catch any of that oncology news out of August?

David Sterling: Which part? There was a lot moving that month.

Megan Skiendel: August 26th specifically. I was sitting with a friend who's a GI oncologist — we were just having coffee — and her phone started going. And she looked up and said, 'They actually did it.' I didn't know what she meant. She said Revolution Medicines just got FDA approval for Rasonque. And the way she said it, I mean, it wasn't excitement exactly. It was more like... relief? Like something overdue had finally arrived.

David Sterling: Thirty years overdue, technically.

Megan Skiendel: That's the part I want to get into, actually — because the FDA didn't just approve a drug on August 26th. They approved the first drug ever in a class called RAS(ON) inhibitors. And the reason that matters is that RAS mutations have been sitting there, visible to cancer biologists, for about thirty years. They knew the problem. They just couldn't touch it.

David Sterling: Wait — thirty years of knowing the target and no drug?

Megan Skiendel: Think of it like a light switch stuck permanently in the ON position — the RAS protein just keeps firing, telling cells to grow. Every cancer biologist knew the switch was there. Nobody could reach it to flip it off. And then Revolution Medicines did, with daraxonrasib. 6.5 months ahead of the FDA's own user fee deadline, Breakthrough Therapy designation, Orphan Drug, Priority Review — three signals stacked on one drug. That's not routine.

David Sterling: Three designations on one approval. The FDA's own director of the Oncology Center of Excellence — Angelo de Claro — called the results 'unprecedented.' That word doesn't come out of that office casually.

Megan Skiendel: And 'unprecedented' from de Claro lands — but then five weeks later the revenue number lands even harder. $197.6 million. August 26 through September 30. That's not a drug finding its feet. That's a drug the market was already waiting for.

David Sterling: Five weeks. Nearly $200 million annualized. That's a run rate that puts it in the top tier of oncology launches — ever.

Megan Skiendel: And that's pure pancreatic. The lung signal didn't break until mid-November. So those five weeks — that's the labeled indication, real prescribers, real patients.

David Sterling: Which is what makes ESMO 2026 so strange to sit next to that number. Alexander Spira presents the vopimetostat combination data — Tango Therapeutics' drug paired with Rasonque — and the ORR in MTAP-deleted pancreatic patients is 82%. In a population where more than half are receiving this as third-line therapy. I mean — third-line. These are patients who've already failed two regimens.

Megan Skiendel: Eighty-two percent in third-line patients — that's not an improvement. That's a different category of drug.

David Sterling: De Claro's 'unprecedented' quote covers both moments, frankly. And the FDA then issued a third Breakthrough Therapy designation — this one for Rasonque in combination with gemcitabine and nab-paclitaxel. That's November 5th. So within ten weeks of approval, the drug has a new combination pathway moving toward the front-line setting.

Megan Skiendel: Wait — third designation? For the same drug?

David Sterling: Third. And Tango is planning the pivotal Phase 3 of vopimetostat plus Rasonque for MTAP-deleted pancreatic cancer — front-line — in H1 2027. That's the tell. The launch revenue says the drug works in the approved label. The ESMO data says the combination unlocks a completely different ceiling. Those two facts aren't — well, they're not really about the same asset anymore.

Megan Skiendel: And Revolution Medicines has $3.7 billion in cash to run all of it. So the question isn't whether they survive long enough to find out — it's whether the platform holds.

David Sterling: But the platform holding is exactly where I want to slow down. Because the lung cancer piece — I think people are treating it as a second data point that confirms the story, and I'm not sure it's that yet.

Megan Skiendel: What do you mean it's not that yet?

David Sterling: The November 13th reports. What do they actually say? Safe. Manageable side effects — rash, diarrhea, nausea. Researchers calling it promising. That's it. No trial phase named, no patient count, no primary endpoint, no quantified response rate for lung cancer in the verified sources. Zero.

Megan Skiendel: I went back and read those reports three times. There's no denominator. The 42% figure that's floating around — I cannot find where that's sourced from in the actual trial record.

David Sterling: So when someone says Rasonque is working in lung cancer — what are they actually saying?

Megan Skiendel: They're saying it's safe in early-stage patients who happen to have KRAS-mutated NSCLC. Which — look, the mechanistic rationale is real. A 2026 Frontiers in Oncology review puts KRAS mutations in up to 30% of NSCLC patients. That's a giant population. But Rasonque has no lung cancer indication filed with the FDA. No EMA submission either. The whole NSCLC story is investigational right now. And meanwhile, Lumakras and Krazati are already on the market, already approved for KRAS G12C specifically in lung cancer. Rasonque's argument is broader mutation coverage — the patients Lumakras and Krazati can't reach. That's the edge. But whether broader coverage actually means better outcomes in those patients? That is completely unsettled.

David Sterling: Right — but the part that doesn't fit is that the market is already pricing the lung story. Imagine an oncologist at a tumor board in, say, Houston this week, looking at a KRAS G12D patient — not G12C, so Lumakras is irrelevant — and reaching for Rasonque off-label because there's nothing else. That's real prescribing behavior. But it's not evidence.

Megan Skiendel: And all of that commercial risk sits inside one jurisdiction. The EMA hasn't approved daraxonrasib. Full stop. So if the lung Phase 3 misses — honestly, we should get into what Revolution Medicines' $3.7 billion runway actually buys them when that scenario runs.

David Sterling: Frankly, that's the number I want to pressure-test next.

Megan Skiendel: So here's what that runway actually buys — not safety, exactly. It buys four Phase 3 trials running simultaneously. RASolve 308, RASolute 309, RASolve 307, and then BeOne is funding RASonate 312 for G12D colorectal. That's the scorecard. Not the November lung signal. Those four trials.

David Sterling: $3.7 billion in cash. $2.1 to $2.2 billion full-year operating expense. You get roughly seven to eight quarters even if NSCLC produces nothing. That's the arithmetic.

Megan Skiendel: And the company didn't revise that guidance upward when the lung signal broke. The $2.1 to $2.2 billion stayed exactly where it was. That's the tell.

David Sterling: Which means the board isn't betting on NSCLC yet. The market is — the company isn't.

Megan Skiendel: So if Phase 3 lung misses — what does the asset actually revert to?

David Sterling: A pancreatic-only drug. With $197.6 million in five weeks, sure, but — I mean, pancreatic cancer is roughly 60,000 new diagnoses a year in the U.S. That ceiling is real. And the EMA still hasn't approved daraxonrasib outside the U.S. Zero international revenue diversification. So you're pricing a global platform off a single-jurisdiction pancreatic label.

Megan Skiendel: And the 82% ORR — wait, that's MTAP-deleted, heavily pretreated patients. That population is not the NSCLC population. Extrapolating that signal to lung, or to first-line settings — the data genuinely don't support that leap yet.

David Sterling: That's the load-bearing problem. Imagine a Revolution Medicines trial team right now, pulling interim data on RASolute 309 — daraxonrasib plus zoldonrasib — and the response curve in lung cancer patients doesn't hold the way MTAP-deleted pancreatic did. That moment, whenever it comes in the next 18 to 24 months, is when the platform thesis either survives or it doesn't.

Megan Skiendel: And we genuinely don't know which way that breaks. That's not a hedge — that's just where the data actually sits right now.

David Sterling: And that trial coordinator enrolling the next patient into RASolve 308 or RASolute 309 — that person is not thinking about the valuation question. They're thinking about the scan they'll read in twelve weeks.

Megan Skiendel: Somewhere right now. Some lung cancer patient walking into a clinic, being told there's a Phase 3 slot open, signing the consent form. They don't know they're the answer to whether Rasonque is a platform or just a very good pancreatic drug dressed up in bigger language. They're just — they want the drug to work.

David Sterling: Yeah. And in 18 months we'll know.